Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	€0.5800	-3.33%	6,039
26-10-16	€0.6000	+7.14%	1,952
26-10-15	€0.5600	-3.78%	3,545
26-10-14	€0.5820	+2.11%	365
26-10-13	€0.5700	-7.47%	1,200

Real-time Euronext Paris

More quotes

Real-time Euronext Paris 07:38:08 2026-10-19 EDT			5-day change	1st Jan Change
0.5800 ^EUR	-3.33%		-5.84%	-33.18%

08-26	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	2.88M 3.24M 2.67M 2.43M 4.58M 307M 4.65M 32.04M 12.56M 160M 12.14M 11.88M 511M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.45M 3.67M 3.34M 6.3M 422M 6.4M 44.09M 17.28M 220M 16.71M 16.35M 703M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Deutsche Boerse AG	4YA	Delayed
Börse Stuttgart	4YA	Delayed
Boerse Muenchen	4YA	Real-time

08-26	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-29	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-15	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-29	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
23-11-07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
23-10-27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-27	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
22-12-23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
22-12-14	Twitter to shut down newsletter product Revue next year	RE
22-12-05	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT

Klarsen Stock

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news: Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Price Extremes

Managers and Directors: Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

10-16	ALKLA – Assemblées générales 2026 : l’ensemble des résolutions adopté Klarsen ouvre une nouvelle séquence de développement – 16 Octobre 2026
10-16	KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
10-06	Klarsen : Assemblée générale – 29 Septembre 2026
09-08	Klarsen : calendrier de communication
09-08	Klarsen : ALKLA – Klarsen fait évoluer son calendrier de communication financière et rappelle la tenue de ses Assemblées Générales des 29 septembre et 8 octobre 2026 – 08 Septembre 2026

1 day	-3.33%
1 week	-5.84%
Current month	+3.20%
1 month	-13.43%
3 months	+52.63%
6 months	-15.20%
Current year	-33.18%

1 week	0.56	0.65
1 month	0.55	0.72
Current year	0.22	1.68
1 year	0.22	1.68
3 years	0.22	3.48
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	2008-06-30
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	2012-12-31

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	2010-06-13
Gérard Parrou BRD	Director/Board Member	74	2014-06-26
Frédéric Bartoli BRD	Director/Board Member	-	2011-03-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/15/22	Parrou Julien	Buy		2,617	0.0790%
2/28/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
2/28/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-3.33%	-5.84%	-30.46%	-81.65%	2.24M
IBM	+0.72%	+2.93%	-17.62%	+69.31%	219B
SALESFORCE, INC.	-0.39%	+2.17%	-6.01%	+14.72%	198B
ACCENTURE PLC	+0.32%	+7.29%	-4.81%	-23.90%	136B
SNOWFLAKE INC.	+3.85%	-11.58%	+29.70%	+107.67%	108B
CLOUDFLARE, INC.	+1.06%	-14.87%	+40.21%	+375.71%	106B
TATA CONSULTANCY SERVICES LTD.	-0.17%	+15.81%	-18.38%	-28.79%	93.97B
RELX PLC	+0.65%	+6.23%	-13.89%	+1.81%	67.63B
INFOSYS LIMITED	-2.63%	+10.85%	-22.60%	-21.13%	49.56B
FUJITSU LIMITED	-1.67%	+2.33%	+17.80%	+151.39%	48.6B
Average	-0.19%	+2.85%	-2.61%	+56.51%	102.59B
Weighted average by Cap.	+0.42%	+1.76%	-1.14%	+68.08%

	2023	2024
Net sales	5.03M 5.65M 4.66M 4.24M 8M 537M 8.13M 55.99M 21.95M 280M 21.22M 20.77M 893M	6.31M 7.1M 5.85M 5.32M 10.04M 674M 10.2M 70.31M 27.57M 352M 26.65M 26.08M 1.12B
Net income	2.75M 3.09M 2.55M 2.32M 4.38M 294M 4.45M 30.65M 12.02M 153M 11.61M 11.37M 489M	-47.76K -53.73K -44.27K -40.28K -76.01K -5.1M -77.23K -532K -209K -2.66M -202K -197K -8.48M
Net Debt	-634K -714K -588K -535K -1.01M -67.74M -1.03M -7.07M -2.77M -35.35M -2.68M -2.62M -113M	1.08M 1.22M 1M 911K 1.72M 115M 1.75M 12.04M 4.72M 60.22M 4.56M 4.47M 192M